Gilead Sciences (GILD) closed at $156.19 on Oct 16, 2026, down 0.7% on the day. The stock is up 3.5% over the past month, up 17.3% over three months, up 28.0% year to date and up 33.7% over the past year. It trades 2.7% below its 52-week high of $160.51 and 38.7% above its 52-week low of $112.63. The close sits above its 50-day moving average ($146.84) and above its 200-day moving average ($137.83).
NextPick tracks GILD in its Pharma basket alongside JNJ, ABBV, MRK, RHHBY and NVS. As of Oct 16, 2026, the basket's money-flow score is -5 (neutral), and the basket is up 3.1% over five sessions. Over the past month GILD ranks 6th of 12 basket members by price change.
GILD is scheduled to report earnings on Oct 22, 2026. Over its last 8 reports the stock moved an average of 4.6% on the first trading day after earnings, beating the options-implied move in 4 of 8.
GILD options were pricing 32% at-the-money implied volatility on Oct 12, 2026, an IV rank of 54 over the past year.
Gilead Sciences is scheduled to report on Oct 22, 2026.
Over the last 8 reports, GILD moved an average of 4.6% on the first trading day after earnings. The move beat the options-implied move in 4 of 8 reports.
Yes — the Oct 16, 2026 close of $156.19 is 13.3% above the 200-day average of $137.83.
GILD closed 2.7% below its 52-week high of $160.51.
NextPick groups GILD with JNJ, ABBV, MRK, RHHBY and NVS in its Pharma basket.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
